Carlos Zetina-Rocha

Title: The Innovations of Carlos Zetina-Rocha

Introduction

Carlos Zetina-Rocha is a notable inventor based in Brantford, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid forms of important drug compounds. With a total of 7 patents to his name, his work has had a substantial impact on the treatment of chronic myelogenous leukemia (CML).

Latest Patents

One of his latest patents is focused on solid forms of nilotinib hydrochloride. This patent discloses various crystalline solvates of nilotinib HCl, including those prepared with benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is recognized as a tyrosine kinase inhibitor that is crucial for treating drug-resistant CML. Another significant patent involves polymorphic forms of lapatinib ditosylate and the processes for their preparation. This patent provides a crystalline form of lapatinib, termed APO-I, along with methods for its production. Additionally, it includes a crystalline solvate form of lapatinib, termed APO-II, and the methods for creating this form.

Career Highlights

Carlos has worked with prominent companies in the pharmaceutical industry, including Apotex Pharmachem Inc. and Apotex Inc. His experience in these organizations has allowed him to refine his skills and contribute to innovative drug development.

Collaborations

Throughout his career, Carlos has collaborated with esteemed colleagues such as Gamini Weeratunga and Stephen E. Horne. These partnerships have fostered a collaborative environment that has led to significant advancements in pharmaceutical research.

Conclusion

Carlos Zetina-Rocha's contributions to the field of pharmaceuticals through his patents and collaborations highlight his dedication to innovation. His work continues to influence the treatment of chronic myelogenous leukemia and showcases the importance of research in developing effective therapies.